Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28385768 | 0.97 | TSHR (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9265602 | 0.80 | TSHR (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL5143751 | 0.77 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3123745 | 0.74 | — | — | |
| SCHEMBL28801076 | 0.74 | TSHR (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL1948808 | 0.74 | — | — | |
| SCHEMBL8351730 | 0.72 | TSHR (0.43) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10414189 | 0.70 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL22802100 | 0.70 | — | — | |
| SCHEMBL3495565 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781445-B2 | Synthesis of indenoisoquinoliniums and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080242692-A1 | Synthesis of Indenoisoquinoliniums and Methods of Use | PURDUE RESEARCH FOUNDATION | 2008-10-02 | — | — | US | disclosed |
| EP-1735281-A2 | SYNTHESIS OF INDENOISOQUINOLINIUMS AND METHODS OF USE | Purdue Research Foundation (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005089294-A2 | SYNTHESIS OF INDENOISOQUINOLINIUMS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2005-09-29 | — | — | WO | disclosed |
| US-5055459-A | Purging leukemic tumor cells from mammals | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 1991-10-08 | — | — | US | disclosed |
| US-4820694-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242692-A1 | Synthesis of Indenoisoquinoliniums and Methods of Use | INMT, QTRT1, QTRT2 | TSHR 3826/4885CHRM2 1945/4885CHRM4 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.